The approval makes brexpiprazole, an atypical antipsychotic, the first and only treatment approved in the United States for this common neuropsychiatric symptom of AD, which is reported in nearly half of those with Alzheimer dementia, according to a joint Otsuka/Lundbeck statment.
FDA Approves Brexpiprazole for Agitation Associated with Alzheimer Dementia
- Post author:Randy Banks
- Post published:May 15, 2023
- Post category:News